维普中文期刊产品整合服务
155篇 您的检索式:作者名="Tomasek"
    题名 作者 年代 出处 被引量
1Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer显示文摘AIM:To perform a comparative analysis of clinicopathological correlations of cyclooxygenase2 (COX2) expression in pancreatic cancer, examined by monoclonal and polyclonal antibodies.METHODS: The COX2 expression in 85 resection specimens of pancreatic ductal adenocarcinoma was immunohistochemically examined using both monoclonal and polyclonal antibodies. The final immunoscores were obtained by multiplying the percentage of positive cells with the numeric score reflecting the staining intensity.COX2 expression levels were classified into three categories (0, 1+, and 2+) and the clinicopathological correlations were statistically evaluated and analyzed.RESULTS: The positive tumor expression rates of COX2 were 80.5% using monoclonal antibody and 69.4% using polyclonal antibody. In the KaplanMeier analysis, no significant correlations were found between levels of COX2 expression and overall survival (OS), but trends to longer OS were found in COX2 negative cases using monoclonal antibody. Significantly longer disease free survival was revealed in COX2 negative cases using monoclonal antibody (P = 0.019). No correlations between COX2 expression levels and grade (G), tumor (T) status and nodal (N) status were demonstrated. Low histological grade showed a strong association with a longer OS (P < 0.001). Correlation of survival and T status revealed a shorter OS in T3 tumors, but the results reached only marginal statistical significance (P = 0.070). In the multivariate Cox proportional hazards regression model, histological grade, T and N status remained valuable predictors of a worse survival with borderline significance for T [hazards ratio (HR) = 4.18 for G (if G = 3, P < 0.001); HR = 1.64 for T (if T = 3, P = 0.065); HR = 2.53 for N (if N = 1, P = 0.006)]. Higher grade, T or N status was associated with a worse OS. CONCLUSION: The immunohistochemically assessed level of COX2 expression does not seem to represent a valuable independent prognostic factor and is not superior to the conventional prognostic factors.Marketa Hermanova Petr Karasek Jiri Tomasek Jiri Lenz Jiri Jarkovsky Petr Dite 2010World Journal of Gastroenterology2010,16,15:7
2Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell 2014The Lancet2014,,9911:3
3Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial显示文摘Charles S Fuchs Jiri Tomasek Cho Jae Yong Filip Dumitru Rodolfo Passalacqua Chanchal Goswami Howard Safran Lucas Vieira dos Santos Giuseppe Aprile David R Ferry Bohuslav Melichar Mustapha Tehfe Eldar Topuzov John Raymond Zalcberg Ian Chau William Campbell 20142014 (9911)2014,,9911:2
4Soot oxidation显示文摘Randy L. Vander Wal Aaron J. Tomasek 2003Combustion and Flame2003,,1:2
5Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton显示文摘Tomasek JJ Halliday NL Updike DL 1997J BiolChem1997,272,:2
6Effects of alumina in nonmetallic brake friction materials on friction performance显示文摘Tomasek V Kratosova G Yun R P 2009J Mater Sci2009,44,:1
7Myofibroblasts and mechano-regulation of connective tissue remodeling显示文摘Tomasek JJ Gabbiani G Hinz B 2002Nat Rev Mol Cell Biol2002,3,:1
8Bile duct malig- nancies 显示文摘Tucek S Tomasek J Hal6mkova J 2010Klin 0nkol2010,23,4:1
9Ramucirumab mono- therapy for previously treated advanced gastric or gastro - oesoph-ageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo - controlled, phase 3 trial 显示文摘FUCHS CS TOMASEK J YONG CJ 2014Lancet2014,383,9911:1
10Myofibroblasts and mechano-regulation of connective tissue remodelling显示文摘Tomasek JJ Gabbiani G Hinz B 2002Nat Rev Mol Cell Biol2002,3,5:1
11Ramucirumabmonotherapyfor previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,Phase 3 trial显示文摘Fuchs CS Tomasek J Yong CJ 2014Lancet2014,383,9911:1
12Myofibroblasts and mechano-regulation of connective tissue remodelling 显示文摘Tomasek JJ Gabbiani G Hinz B 2002Nat Rev Mol Cell Biol2002,3,5:1
13Soot nanostructure:Dependence upon synthesis conditions显示文摘Vander Wal R L Tomasek A J 2004Combustion andFlame2004,136,1:1
14Ramucirumab monothera- py for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma ( REGARD ) : an international, ran- domised, multicentre, placebo-cantrolled, phase 3 trial 显示文摘Fuchs CS Tomasek J Yong CJ 2014Lancet2014,383,9911:1
15Effects of alumina in nonmetallic brake friction materials on friction perfor- mance显示文摘Tomasek V Kratosova G Yun R 2009J Mater Sci2009,44,1:1
16Myofibroblasts and mechanoregulation of connective tissue remodelling显示文摘Tomasek JJ Gabbiani G Hinz B 2002Nat Rev Mol Cell Biol2002,3,5:1
17Myofibroblasts and mechano-regulation of connective tissue remodeling显示文摘Tomasek JJ Gabbiani G Hinz B 2002Nat Rev Mol Cell Biol2002,3,5:1
18Ramucirumabmonotherapy for previously treated advanced gastric orgastro-oesophageal junction adenocarcinoma (REGARD}:an international, randomised, multicen- tre, placebo-controlled,phase 3 trial显示文摘Fuchs CS Tomasek J Yong CJ 2014Lancet2014,383,9911:1
19Characteriza-tion of cultured bladder smooth muscle ells:assessment of invitro contractility显示文摘KROPP BP ZHANG Y TOMASEK JJ 1999J Urol1999,162,:1
20Soot oxidation: Dependence upon initial nanostrucmre显示文摘Vander Wal R L Tomasek A J 2004Combustion andFlame2004,134,12:1
返回顶部 每页显示:
共8页 首页 上一页 第1页 下一页 末页 /8 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费